Drug Discovery Study Aimed at a Functional Cure for HBV

Area of Science:

• Hepatology
• Virology
• Drug Development

Background:

• Chronic hepatitis B (CHB) affects millions globally, with limited functional cure rates from current antivirals.
• Hepatitis B virus (HBV) replication and persistence are complex, necessitating novel therapeutic strategies.
• Accurate monitoring of viral activity and treatment response is crucial for managing CHB.

Purpose of the Study:

• To review the current developmental status of novel therapeutic agents for CHB.
• To highlight direct-acting antiviral agents (DAAs) targeting HBV-DNA and HBV-RNA.
• To discuss the role of emerging serological biomarkers, such as HBcrAg, in CHB management.

Main Methods:

• Literature review of recent advancements in HBV therapeutics.
• Analysis of drugs targeting HBV-DNA and HBV-RNA, including DAAs.
• Evaluation of serological biomarkers for predicting clinical course and monitoring treatment.

Main Results:

• Several novel agents targeting HBV-DNA and HBV-RNA are in development, showing promise.
• Direct-acting antiviral agents (DAAs) are a key focus in current HBV drug development.
• Hepatitis B core-associated antigen (HBcrAg) assay is a sensitive marker for HBV activity, potentially replacing HBV DNA testing.
• Many investigational drugs demonstrate efficacy in reducing hepatitis B surface antigen (HBsAg) levels.

Conclusions:

• Novel DAAs and combination therapies offer new hope for achieving functional cure in CHB.
• HBcrAg represents a significant advancement in monitoring HBV activity and treatment efficacy.
• Further research into optimal drug combinations and immune-boosting strategies is essential for advancing CHB therapy.